March 5, 2018 / 12:29 PM / 3 months ago

BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing

March 5 (Reuters) - Zynerba Pharmaceuticals Inc:

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING

* ZYNERBA - EXPECTS TO INITIATE SINGLE PIVOTAL STUDY MID-YEAR 2018 TO SUPPORT NDA FOR ZYN002 IN FXS

* ZYNERBA PHARMACEUTICALS SAYS FDA & CO ARE IN AGREEMENT OVER PRIMARY & KEY SECONDARY ENDPOINTS FOR ZYN002 IN FRAGILE X SYNDROME Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below